ProCE Banner Activity

SIRFLOX: Addition of SIRT to mFOLFOX6 ± Bevacizumab in First-line mCRC Improves Liver Disease Control

Slideset Download
Conference Coverage
Addition of SIRT to chemotherapy first-line treatment of metastatic CRC did not improve overall PFS or ORR, but substantially reduced the risk of disease progression in the liver.

Released: June 01, 2015

Expiration: May 30, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation